MacuLogix, a Harrisburg, Pennsylvania-based company that equips eye care professionals with the instruments, tools, and education they need to effectively diagnose and treat patients with age-related macular degeneration (AMD), has raised $38.7 million in Series D funding. This round of funding was led by new investor Vivo Capital. Existing investors Fisk Ventures, Roche Venture Fund, Berwind Private Equity and Life Sciences Greenhouse of Central Pennsylvania also participated. Including this round, MacuLogix has raised a total of $51 million in venture funding and $10 million in venture debt.
“AMD is the leading cause of adult blindness in the Western world because we haven’t had the technology or tools to effectively detect and manage this progressive, chronic disease – until now. Our company is determined to see AdaptDx functional testing become the standard of care, enabling eye care professionals to detect, treat and manage AMD earlier and more effectively,” said MacuLogix president and CEO Bill McPhee in a statement. “With this funding and the addition of Vivo Capital, we are fully backed by a strategic group of investors who support our company’s vision to eliminate blindness caused by AMD.”
With this funding round, MacuLogix is going to further expand its team and company infrastructure to support the growing sales and practice integration efforts of the AdaptDx automated dark adaptometer domestically and internationally.
In conjunction with this round of funding, Vivo Capital managing director Jack Bech Nielsen, Vivo Capital Principal Nathan Dau, and Roche Venture Fund head Carole Nuechterlein are joining MacuLogix’s board of directors. The other board members include McPhee along with MacuLogix CTO and co-founder Gregory Jackson, Fisk Ventures managing director Stephen Rose, and Life Sciences Greenhouse of Central Pennsylvania SVP Ronald Thiboutot.
“Maculogix is entering a rapid commercial expansion phase and is a very good fit for our investment strategy,” added Nielsen. “The AdaptDx is uniquely situated to help patients being diagnosed at an early stage of AMD and enable better and earlier monitoring and treatment of the disease.”
